Clinical trial
Angiomax in Patients With HIT/HITTS Type II Undergoing CPB
NCT00079508 · The Medicines Company, Industry · Completed
Key facts
| NCT number | NCT00079508 |
|---|---|
| Title | Angiomax in Patients With HIT/HITTS Type II Undergoing CPB |
| Official title | A Phase III Study of Angiomax (Bivalirudin) in Patients With HIT/HITTS Type II Undergoing Cardiac Surgery on Cardiopulmonary Bypass (CPB) |
| Acronym | HIT/TS |
| Lead sponsor | The Medicines Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cardiovascular Disease, Coronary Artery Bypass Surgery |
| Intervention type | Drug |
| Interventions | Angiomax (bivalirudin) |
| Enrollment | 125 |
| Start date | Apr 1, 2004 |
| Primary completion | Oct 1, 2005 |
| First posted | Mar 11, 2004 |
| Last update posted | Nov 10, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: